Cargando…

Asphericity of Somatostatin Receptor Expression in Neuroendocrine Tumors: An Innovative Predictor of Outcome in Everolimus Treatment?

Background: in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NET), the mTOR inhibitor everolimus is associated with significant improvement in progression-free survival (PFS). This study evaluated the lesional asphericity (ASP) in pretherapeutic somatostatin receptor (SSR) imaging...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wetz, Christoph, Rogasch, Julian, Genseke, Philipp, Schatka, Imke, Furth, Christian, Kreissl, Michael, Jann, Henning, Venerito, Marino, Amthauer, Holger
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7554807/ https://www.ncbi.nlm.nih.gov/pubmed/32971877 http://dx.doi.org/10.3390/diagnostics10090732

Ejemplares similares

The association of intra-therapeutic heterogeneity of somatostatin receptor expression with morphological treatment response in patients undergoing PRRT with [(177)Lu]-DOTATATE
por: Wetz, Christoph, et al.
Publicado: (2019)

The Prognostic Value of the De Ritis Ratio for Progression-Free Survival in Patients with NET Undergoing [(177)Lu]Lu-DOTATOC-PRRT: A Retrospective Analysis
por: Ruhwedel, Tristan, et al.
Publicado: (2021)

Somatostatin Analogues in the Treatment of Neuroendocrine Tumors: Past, Present and Future
por: Stueven, Anna Kathrin, et al.
Publicado: (2019)

Asphericity of tumor FDG uptake in non-small cell lung cancer: reproducibility and implications for harmonization in multicenter studies
por: Rogasch, Julian M. M., et al.
Publicado: (2020)

ChatGPT: Can You Prepare My Patients for [(18)F]FDG PET/CT and Explain My Reports?
por: Rogasch, Julian M.M., et al.
Publicado: (2023)

Pretherapeutic FDG-PET total metabolic tumor volume predicts response to induction therapy in pediatric Hodgkin’s lymphoma
por: Rogasch, Julian M. M., et al.
Publicado: (2018)

Same same but different: dopamine transporter SPECT on scanners with CZT vs. NaI detectors
por: Thiele, Felix, et al.
Publicado: (2023)

Prognostic Value of the Largest Lesion Size for Progression-Free Survival in Patients with NET Undergoing Salvage PRRT with [(177)Lu]Lu-DOTATOC
por: Galler, Markus, et al.
Publicado: (2022)

Quantitative assessment of the asphericity of pretherapeutic FDG uptake as an independent predictor of outcome in NSCLC
por: Apostolova, Ivayla, et al.
Publicado: (2014)

A rare case of a patient with a high grade neuroendocrine tumor developing neutropenic sepsis after receiving PRRT combined with Capecitabine or Temozolomide: A case report
por: Özdirik, Burcin, et al.
Publicado: (2021)

Selective Internal Radiation Therapy in Breast Cancer Liver Metastases: Outcome Assessment Applying a Prognostic Score
por: Schatka, Imke, et al.
Publicado: (2021)

Shortened Tracer Uptake Time in GA-68-DOTATOC-PET of Meningiomas Does Not Impair Diagnostic Accuracy and PET Volume Definition
por: Graef, Josefine, et al.
Publicado: (2020)

Efficacy and Safety of Everolimus plus Somatostatin Analogues in Patients with Neuroendocrine Tumors
por: Ge, Wenhao, et al.
Publicado: (2018)

An optimized imaging protocol for [(99m)Tc]Tc-DPD scintigraphy and SPECT/CT quantification in cardiac transthyretin (ATTR) amyloidosis
por: Schatka, Imke, et al.
Publicado: (2021)

Explorative analysis of a score predicting the therapy response of patients with metastatic, castration resistant prostate cancer undergoing radioligand therapy with (177)Lu-labeled prostate-specific membrane antigen
por: Huang, Kai, et al.
Publicado: (2020)

Transarterial Yttrium-90 Radioembolization in Intrahepatic Cholangiocarcinoma Patients: Outcome Assessment Applying a Prognostic Score
por: Schatka, Imke, et al.
Publicado: (2022)

Influence of rigid coregistration of PET and CT data on metabolic volumetry: a user’s perspective
por: Steffen, Ingo G, et al.
Publicado: (2013)

Combination of tumor asphericity and an extracellular matrix-related prognostic gene signature in non-small cell lung cancer patients
por: Zschaeck, Sebastian, et al.
Publicado: (2023)

Prognostic value of baseline [(18)F]-fluorodeoxyglucose positron emission tomography parameters MTV, TLG and asphericity in an international multicenter cohort of nasopharyngeal carcinoma patients
por: Zschaeck, Sebastian, et al.
Publicado: (2020)

Reconstructed spatial resolution and contrast recovery with Bayesian penalized likelihood reconstruction (Q.Clear) for FDG-PET compared to time-of-flight (TOF) with point spread function (PSF)
por: Rogasch, Julian M., et al.
Publicado: (2020)

Long-term treatment with streptozocin/5-fluorouracil chemotherapy in patients with metastatic pancreatic neuroendocrine tumors: Case series
por: Müller, Christian, et al.
Publicado: (2022)

A case report of an excellent response to interferon- α in a patient with functional metastasized neuroendocrine tumor refractory to other treatments
por: Özdirik, Burcin, et al.
Publicado: (2020)

Correlation Between Quantitative PSMA PET Parameters and Clinical Risk Factors in Non-Metastatic Primary Prostate Cancer Patients
por: Zschaeck, Sebastian, et al.
Publicado: (2022)

Everolimus-induced somatostatin receptor overexpression in a rectal neuroendocrine tumor patient may promote somatostatin receptor-guided radionuclide therapy (peptide receptor radiotherapy) as an additional treatment option
por: Mileva, Magdalena, et al.
Publicado: (2020)

Neurofilament Levels Are Reflecting the Loss of Presynaptic Dopamine Receptors in Movement Disorders
por: Diekämper, Elena, et al.
Publicado: (2021)

Inferring FDG-PET-positivity of lymph node metastases in proven lung cancer from contrast-enhanced CT using radiomics and machine learning
por: Gorodetski, Boris, et al.
Publicado: (2022)

Somatostatin and Somatostatin Receptors: From Signaling to Clinical Applications in Neuroendocrine Neoplasms
por: del Olmo-Garcia, Maria Isabel, et al.
Publicado: (2021)

Anti-proliferative and anti-secretory effects of everolimus on human pancreatic neuroendocrine tumors primary cultures: is there any benefit from combination with somatostatin analogs?
por: Mohamed, Amira, et al.
Publicado: (2017)

Role of Somatostatin Signalling in Neuroendocrine Tumours
por: Rogoza, Olesja, et al.
Publicado: (2022)

The association of tumor-to-background ratios and SUVmax deviations related to point spread function and time-of-flight F18-FDG-PET/CT reconstruction in colorectal liver metastases
por: Rogasch, Julian MM, et al.
Publicado: (2015)

Performance of Deauville Criteria in ([18F])FDG-PET/CT Diagnostics of Giant Cell Arteritis
por: Siefert, Jeffrey, et al.
Publicado: (2023)

Epigenetic regulation of somatostatin and somatostatin receptors in neuroendocrine tumors and other types of cancer
por: Klomp, M.J., et al.
Publicado: (2020)

Emerging use of everolimus in the treatment of neuroendocrine tumors
por: Gajate, Pablo, et al.
Publicado: (2017)

The influence of different signal-to-background ratios on spatial resolution and F18-FDG-PET quantification using point spread function and time-of-flight reconstruction
por: Rogasch, Julian MM, et al.
Publicado: (2014)

Somatostatin-Dopamine Chimeric Molecules in Neuroendocrine Neoplasms
por: Cantone, Maria Celeste, et al.
Publicado: (2021)

CT radiomics to predict Deauville score 4 positive and negative Hodgkin lymphoma manifestations
por: Jensen, Laura J., et al.
Publicado: (2022)

Safety and Efficacy of Everolimus in Adult Patients with Neuroendocrine Tumors
por: Oberstein, Paul E., et al.
Publicado: (2012)

Everolimus and mTOR inhibition in pancreatic neuroendocrine tumors
por: Yim, Kein-Leong
Publicado: (2012)

Anti-tumour activity of everolimus and sunitinib in neuroendocrine neoplasms
por: Daskalakis, Kosmas, et al.
Publicado: (2019)

Interaction between somatostatin analogues and targeted therapies in neuroendocrine tumor cells
por: Krug, Sebastian, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ljdo3h4nf9klav14ocep6b74bc